COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,903 Articles (22,568 medRxiv, 8,335 bioRxiv)

Most recent first Previous |  Page 873: Articles 8721-8730  | Next

Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2
Smid, M., Berec, L., Majek, O., Pavlik, T., Jarkovsky, J., Pribylova, L., Weiner, J., Barusova, T., Trnka, J.
10.1101/2022.02.24.22271396 — Posted: 2022-02-25
CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2
Kozlovskaya, L. I., Gordeychuk, I., Piniaeva, A., Kovpak, A., Shishova, A., Lunin, A., Shustova, E., Apolokhov, V., Fominykh, K., Ivin, Y., Kondrashova, A., Volok, V., Tcelykh, I., Siniugina, A., Ishmukhametov, A. A.
10.1101/2022.02.10.22270781 — Posted: 2022-02-25
Mitoquinone mesylate targets SARS-CoV-2 and associated lung inflammation through host pathways
Petcherski, A., Sharma, M., Daskou, M., Satta, S., Vasilopoulos, H., Hugo, C., Ritou, E., Dillon, B. J., Fung, E., Garcia, G., Scafoglio, C., Purkayastha, A., Gomperts, B., Fishbein, G. A., Arumugaswami, V., Liesa, M., Shirihai, O. S., Kelesidis, T.
10.1101/2022.02.22.481100 — Posted: 2022-02-25
When mistrust in the government and scientists reinforce social inequalities in vaccination against Covid-19
Bajos, N., Spire, A., Silberzan, L., Sireyjol, A., Jusot, F., Meyer, L., Franck, J.-E., Warszawski, J.
10.1101/2022.02.23.22271397 — Posted: 2022-02-24
Long-term Durable Humoral Immune Response to Heterologous Antigenic Exposure Post six months by Natural SARS-CoV-2 Infection and Vaccination
Batra, G., Murugesan, D. R., Das, S. J., Chattopadhyay, S., Mehdi, F., Ayushi, , Gosain, M., Singh, S., Deshpande, S., Bhattacharya, J., Pandey, A. K., Jha, S., Goswami, S., Das, A., Dwivedi, T., Sharma, N., Kumar, S., Sharma, P., Kapoor, S., Kshetrapal, P., Wadhwa, N., Thiruvengadam, R., Kumar, R., Gupta, R., Garg, P. K., Bhatnagar, S., DBT Consortium for COVID-19 Research
10.1101/2022.02.23.22271381 — Posted: 2022-02-24
Olfactory loss is an early and reliable marker for COVID-19
Iravani, B., Arshamian, A., Lundstrom, J. N.
10.1101/2022.02.23.22271409 — Posted: 2022-02-24
Challenges and Opportunities Experienced by Performing Artists during COVID-19 Lockdown: Scoping Review
Brooks, S. K., Patel, S. S.
10.1101/2022.02.23.22271390 — Posted: 2022-02-24
COVID-19 mortality in the United States: It's been two Americas from the start
Stoto, M., Schlageter, S., Kraemer, J. A.
10.1101/2022.02.23.22271411 — Posted: 2022-02-24
Genomic surveillance of SARS-CoV-2 reveals emergence of Omicron BA.2 in Islamabad, Pakistan
Umair, M., Ikram, A., Rehman, Z., Haider, S. A., Ammar, M., Badar, N., Ali, Q., Rana, M. S., Salman, M.
10.1101/2022.02.23.22271372 — Posted: 2022-02-24
Quantifying antibody dynamics of severe and non-severe patients with COVID-19
Ordonez-Jimenez, F., Blanco-Rodriguez, R., Almocera, A. E. S., Chinney-Herrera, G., Hernandez Vargas, E. A.
10.1101/2022.02.23.22271403 — Posted: 2022-02-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).